Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Sponsor: Pharmacosmos A/S

Sponsor score: 0

ClinicalTrials ID:NCT07473128

This clinical trial evaluates the myeloprotective effect of trilaciclib in subjects with limited-stage small cell lung cancer. Participants, who must have a confirmed diagnosis and measurable disease, will be randomized to receive either trilaciclib or a saline placebo via intravenous infusion. Eligibility requires recovery from prior surgeries and informed consent.

Patient Parameters

Program Overview

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:

Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?

Participants will be randomised to receive either trilaciclib or placebo.

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
  • Complete recovery from prior anti-tumor surgical procedures
  • Measurable and evaluable disease through tumor assessment
  • Willingness to participate and sign informed consent form

Exclusion Criteria

  • Extensive Stage Small Cell Lung Cancer
  • Active cardiovascular disease
  • Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
  • Pregnant or nursing women

Locations

FACILITYZIPCITYSTATE
Pharmacosmos Investigational Site48073OaklandCalifornia

Get This Program In Your Inbox

You can sign up and apply your patients for this program.